MedTrace Logo

Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01031992 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2009-12-15

No results posted yet for this study

Summary

Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can

1. improve anemia (lead to an increased hemoglobin level)
2. reduce nosebleeds.

Conditions

  • Hereditary Hemorrhagic Telangiectasia

Interventions

DRUG

Tranexamic acid first, than placebo

For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.

DRUG

First placebo, than Tranexamic acid.

First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.

Sponsors & Collaborators

  • Pharmacia GmbH, Erlangen, Germany

    collaborator UNKNOWN

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • University Hospital, Saarland

    lead OTHER

Principal Investigators

  • Urban W Geisthoff, Priv.-Doz. Dr.med. · Medical Faculty of the University of the Saarland and Hospitals of the City of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2002-08-31
Completion
2002-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01031992 on ClinicalTrials.gov